Novo Nordisk (NYSE: NVO) today unveiled a corporate rebrand centred on “Lasting Health Starts Now” and the single “Novo” name, together with an updated corporate culture, “The Novo Way”, designed to enable the company to move ahead with greater focus, speed and impact – marking the beginning of its next chapter. The rebrand and “The Novo Way” are part of how the company will deliver on its business objectives and its ambition to bring better health to many more people.
Announcement Snapshot
| Item | Detail |
|---|---|
| Company | Novo Nordisk (NYSE: NVO); Novo Nordisk A/S remains the legal global company name |
| Announcement | Corporate rebrand + updated corporate culture – 14 Sep 2026 |
| Brand Platform | “Lasting Health Starts Now” |
| Everyday Name | “Novo” |
| Culture Framework | “The Novo Way” – four guiding principles |
| Visual Identity | Modernized expression retaining the tradition‑rooted Apis bull logo |
| Strategic Intent | Greater focus, speed and impact; relevance in a consumer‑driven healthcare market |
The Rebrand – “Lasting Health Starts Now”
- Core Idea: Lasting health begins today, not someday – delivered through progress people see and feel every day.
- Unified Identity: The rebrand gives the company a unique, recognizable and consistent way to connect with people, partners and stakeholders worldwide; “Novo” becomes the everyday name while Novo Nordisk A/S remains the legal entity name.
- Visual Refresh: The updated identity keeps the Apis bull logo rooted in Novo’s heritage while giving the brand a modern, future‑fit expression.
- Consumer Relevance: Designed to be more memorable and closer to how people engage with health today, reflecting the ambition to bring breakthrough science closer to daily life and to strengthen recognition and trust as Novo reaches more people in more ways.
Corporate Culture – “The Novo Way”
Launched today, “The Novo Way” is a new set of principles underpinning company culture, built on more than a century of defining strengths – breakthrough science, deep expertise, care for people, and an unwavering commitment to patient safety – while prescribing the behaviors and ways of working needed to innovate and lead in a faster, more competitive and increasingly consumer‑driven market. It is structured around four principles:
- Customer First: Innovate with consumers and patients at the centre.
- Competitiveness: Raise performance to create greater value for all stakeholders.
- Clarity: Create focus and speed through clear priorities, simple ways of working, and decisive action.
- Care & Integrity: Care for and respect employees; never compromise on patient safety and ethics.
Leadership Commentary
- Mike Doustdar, President & CEO, Novo: “People have always been at the heart of Novo’s science. We have transformed major areas of healthcare by bringing innovation to diseases that affect millions of lives. But the unmet need remains enormous, and at the same time people’s expectations of healthcare are changing. Healthcare must become more responsive, more relevant and easier to fit into everyday life. Our brand and culture are strategically important and will strengthen how we operate and compete, but our reason for being does not change. We remain true to our purpose of changing lives, with ambition for the future – helping people have lasting health, starting now.”
- Tania Sabroe, EVP People, Organisation & Corporate Affairs, Novo: “Brand and culture go hand in hand: culture shapes how we deliver our strategy and our work, while brand shapes how people value our products and services and how our company is perceived around the world. Our updated culture will allow us to focus and move fast, and our rebrand ensures relevance and distinctiveness across medicines, partnerships, marketing and stakeholder engagement. Together, these will sharpen our competitive edge and strengthen our role as a trusted partner in healthcare.”
Market Impact & Outlook
- Strategic Signal: The rebrand and culture reset accompany Novo Nordisk’s push to defend and extend its leadership in obesity and diabetes care, markets that are becoming faster‑moving and increasingly consumer‑facing.
- Operational Intent: “The Novo Way” principles – clarity, competitiveness, customer‑first – read as an internal mandate for faster decision‑making and execution amid intensifying competition in the incretin and obesity treatment space.
- Brand Equity: Retaining the Apis bull preserves over a century of trust capital while the single “Novo” name simplifies global brand architecture across medicines, partnerships and marketing.
- Financial Impact: No financial targets, restructuring costs, or timeline details tied to the rebrand were disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Novo Nordisk’s brand and culture strategy, operational execution, and competitive positioning. Actual results may differ due to risks including market dynamics in obesity and diabetes care, regulatory developments, execution of strategic priorities, and competitive pressures.-Fineline Info & Tech
